Effects of Semaglutide on CKD in Patients With Type 2 Diabetes

被引：0
|
作者：
Kotwal, Sradha S. [1 ,2 ]
Perkovic, Vlado [1 ,3 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Renal & Metab Div, Sydney, NSW, Australia
[2] Prince Wales Hosp, Dept Nephrol, Sydney, NSW, Australia
[3] Univ New South Wales, Fac Med, Sydney, NSW, Australia
来源：
KIDNEY INTERNATIONAL REPORTS | 2025年 / 10卷 / 02期
关键词：
KIDNEY; OUTCOMES; GLP-1;
D O I：
10.1016/j.ekir.2024.11.1365
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：287 / 290
页数：4
相关论文
共 50 条
  • [21] Cardiovascular and CKD-Related Healthcare Costs for Patients with Type 2 Diabetes and CKD
    Singh, Rakesh
    Song, Jinlin
    Faust, Elizabeth
    Du, Yuxian
    Kong, Sheldon X.
    Betts, Keith A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 272 - 272
  • [22] PHARMACOLOGICAL MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH CKD
    Hamilton, Catherine A.
    JOURNAL OF RENAL CARE, 2012, 38 : 59 - 66
  • [23] Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
    Overgaard, Rune V.
    Delff, Philip H.
    Petri, Kristin C. C.
    Anderson, Thomas W.
    Flint, Anne
    Ingwersen, Steen H.
    DIABETES THERAPY, 2019, 10 (02) : 649 - 662
  • [24] Semaglutide for the Treatment of Type 2 Diabetes Mellitus
    Miles, Kaitlin E.
    Kerr, Jessica L.
    JOURNAL OF PHARMACY TECHNOLOGY, 2018, 34 (06) : 281 - 289
  • [25] Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
    Iijima, Takahiro
    Makoto, Shibuya
    Ito, Yuzuru
    Terauchi, Yasuo
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (06) : 774 - 781
  • [26] Safety of injectable semaglutide for type 2 diabetes
    Peter, Rajesh
    Bain, Steve C.
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (07) : 785 - 798
  • [27] Oral semaglutide for the treatment of type 2 diabetes
    Hedrington, Maka S.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 133 - 141
  • [28] Semaglutide Approved indication: type 2 diabetes
    不详
    AUSTRALIAN PRESCRIBER, 2020, 43 (04) : 137 - 139
  • [29] Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
    Rune V. Overgaard
    Philip H. Delff
    Kristin C. C. Petri
    Thomas W. Anderson
    Anne Flint
    Steen H. Ingwersen
    Diabetes Therapy, 2019, 10 : 649 - 662
  • [30] Oral Semaglutide (Rybelsus) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1583): : 166 - 168
12345